{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "interpro:IPR024704",
      "entity_text" : "SMC",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5291",
      "entity_text" : "imatinib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "XREF_BIBR Subsequent to the hypothesis that imatinib inhibits PDGFR signaling, prevents abundant SMC and fibroblast proliferation, and inhibits abundant ECM accumulation, imatinib has been tested for the management of several fibrotic diseases (e.g., dermal and liver pulmonary fibrosis, systemic sclerosis).",
  "reading_complete" : "2020-08-03T15:04:00Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T15:02:12Z",
  "trigger" : "prevents",
  "evidence" : [ "imatinib inhibits PDGFR signaling, prevents abundant SMC" ],
  "pmc_id" : "6524858",
  "score" : 0
}